Drugs / MegaLT Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07696767 | Jul → Dec 2026 expected | hematopoietic and lymphoid system neoplasm, thrombocytopenia | Anhui Provincial Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MegaLT Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07696767 ↗ |
| Modality | Cell therapy | “megakaryocyte cell product” NCT07696767 ↗ |
| Route | Intravenous | “Participants will receive MegaLT Injection by intravenous infusion on day 14 after umbilical cord blood transplantation.” NCT07696767 ↗ |